Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
Mazard T, Causse A, Simony J, Leconet W, Vezzio-Vie N, Torro A, Jarlier M, Evrard A, Del Rio M, Assenat E, Martineau P, Ychou M, Robert B, Gongora C.
Mazard T, et al. Among authors: simony j.
Mol Cancer Ther. 2013 Oct;12(10):2121-34. doi: 10.1158/1535-7163.MCT-12-0966. Epub 2013 Aug 19.
Mol Cancer Ther. 2013.
PMID: 23960095
Free article.